Suppr超能文献

PD-1/PD-L轴表达与黑色素瘤及其他实体瘤的细胞溶解活性、突变负荷和预后的相关性

Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.

作者信息

Danilova Ludmila, Wang Hao, Sunshine Joel, Kaunitz Genevieve J, Cottrell Tricia R, Xu Haiying, Esandrio Jessica, Anders Robert A, Cope Leslie, Pardoll Drew M, Drake Charles G, Taube Janis M

机构信息

Department of Oncology, The Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287.

Vavilov Institute of General Genetics, Russian Academy of Science, Moscow, Russia, 119333.

出版信息

Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7769-E7777. doi: 10.1073/pnas.1607836113. Epub 2016 Nov 11.

Abstract

Programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockade has led to remarkable and durable objective responses in a number of different tumor types. A better understanding of factors associated with the PD-1/PD-L axis expression is desirable, as it informs their potential role as prognostic and predictive biomarkers and may suggest rational treatment combinations. In the current study, we analyzed PD-L1, PD-L2, PD-1, and cytolytic activity (CYT) expression, as well as mutational density from melanoma and eight other solid tumor types using The Cancer Genome Atlas database. We found that in some tumor types, PD-L2 expression is more closely linked to Th1/IFNG expression and PD-1 and CD8 signaling than PD-L1 In contrast, mutational load was not correlated with a Th1/IFNG gene signature in any tumor type. PD-L1, PD-L2, PD-1, CYT expression, and mutational density are all positive prognostic features in melanoma, and conditional inference modeling revealed PD-1/CYT expression (i.e., an inflamed tumor microenvironment) as the most impactful feature, followed by mutational density. This study elucidates the highly interdependent nature of these parameters, and also indicates that future biomarkers for anti-PD-1/PD-L1 will benefit from tumor-type-specific, integrated, mRNA, protein, and genomic approaches.

摘要

程序性细胞死亡蛋白-1(PD-1)/程序性死亡配体-1(PD-L1)免疫检查点阻断已在多种不同肿瘤类型中引发显著且持久的客观反应。深入了解与PD-1/PD-L轴表达相关的因素很有必要,因为这有助于明确它们作为预后和预测生物标志物的潜在作用,并可能提示合理的联合治疗方案。在本研究中,我们使用癌症基因组图谱数据库分析了黑色素瘤及其他八种实体瘤类型中PD-L1、PD-L2、PD-1的表达和细胞溶解活性(CYT),以及突变密度。我们发现,在某些肿瘤类型中,与PD-L1相比,PD-L2表达与Th1/IFNG表达以及PD-1和CD8信号传导的联系更为紧密。相反,在任何肿瘤类型中,突变负荷均与Th1/IFNG基因特征无关。在黑色素瘤中,PD-L1、PD-L2、PD-1、CYT表达及突变密度均为阳性预后特征,条件推断模型显示PD-1/CYT表达(即炎症性肿瘤微环境)是最具影响力的特征,其次是突变密度。本研究阐明了这些参数之间高度相互依存的性质,同时表明未来抗PD-1/PD-L1生物标志物将受益于肿瘤类型特异性、综合的mRNA、蛋白质和基因组方法。

相似文献

1
Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7769-E7777. doi: 10.1073/pnas.1607836113. Epub 2016 Nov 11.
3
The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma.
J Oral Pathol Med. 2018 Aug;47(7):683-690. doi: 10.1111/jop.12722. Epub 2018 May 16.
6
Profiles of PD-1, PD-L1, PD-L2 in Gastric Cancer and Their Relation with Mutation, Immune Infiltration, and Survival.
Biomed Res Int. 2020 Jun 6;2020:2496582. doi: 10.1155/2020/2496582. eCollection 2020.
7
Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
J Gastroenterol Hepatol. 2019 Jul;34(7):1201-1207. doi: 10.1111/jgh.14520. Epub 2018 Nov 18.
8
Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Cancer Res Treat. 2017 Jan;49(1):246-254. doi: 10.4143/crt.2016.066. Epub 2016 Jul 7.
9
PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
Front Immunol. 2020 Dec 17;11:596825. doi: 10.3389/fimmu.2020.596825. eCollection 2020.
10
Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.
Leuk Lymphoma. 2019 Feb;60(2):376-384. doi: 10.1080/10428194.2018.1480767. Epub 2018 Jul 22.

引用本文的文献

3
CD161, a promising prognostic biomarker in hepatocellular carcinoma, correlates with immune infiltration.
PeerJ. 2025 Mar 17;13:e19055. doi: 10.7717/peerj.19055. eCollection 2025.
5
Exploring the Immune Landscape of ccRCC: Prognostic Signatures and Therapeutic Implications.
J Cell Mol Med. 2024 Nov;28(22):e70212. doi: 10.1111/jcmm.70212.
6
Biological characteristics and clinical management of uveal and conjunctival melanoma.
Oncol Res. 2024 Jul 17;32(8):1265-1285. doi: 10.32604/or.2024.048437. eCollection 2024.
7
PD-L2 mediates tobacco smoking-induced recruitment of regulatory T cells via the RGMB/NFκB/CCL20 cascade.
Cell Biol Toxicol. 2024 Jul 23;40(1):56. doi: 10.1007/s10565-024-09892-3.
8
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee.
J Immunother Cancer. 2024 Jul 20;12(7):e009427. doi: 10.1136/jitc-2024-009427.

本文引用的文献

1
B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer.
Oncol Lett. 2016 Mar;11(3):1841-1846. doi: 10.3892/ol.2016.4128. Epub 2016 Jan 19.
4
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
Cancer Discov. 2016 Feb;6(2):202-16. doi: 10.1158/2159-8290.CD-15-0283. Epub 2015 Dec 8.
5
CANCER. The odds of immunotherapy success.
Science. 2015 Oct 9;350(6257):158-9. doi: 10.1126/science.aad4140.
6
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
7
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Science. 2015 Oct 9;350(6257):207-211. doi: 10.1126/science.aad0095. Epub 2015 Sep 10.
9
A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.
Cancer Res. 2015 Sep 15;75(18):3800-11. doi: 10.1158/0008-5472.CAN-15-1082. Epub 2015 Jul 24.
10
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Nat Rev Cancer. 2015 Aug;15(8):457-72. doi: 10.1038/nrc3973.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验